ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced ...

Sometimes, the right advances in medicine catch the public’s imagination—opening a world of possibilities that inspires ...

Lembas ( an AI-powered bioactive peptide discovery company, has emerged from stealth mode with a scientific breakthrough in ...

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

lending weight to the hypothesis that the GLP-1 may reduce craving for alcohol and nicotine via a similar mechanism to its ability to reduce food cravings and help people achieve weight loss.

For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

Women who use an oral contraceptive might want to consider using a back-up method after starting a weight loss drug.

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Back-to-back studies map complementary hunger and satiety pathways, offering clues to refine weight-loss drugs.